The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Developments in Post-marketing Comparative Effectiveness Research
Open accessAbstract
Physicians and insurers need to weigh the effectiveness of new drugs against existing therapeutics in routine care to make decisions about treatment and formularies. Because Food and Drug Administration (FDA) approval of most new drugs requires demonstrating efficacy and safety against placebo, there is limited interest by manufacturers in conducting such head-to-head trials. Comparative effectiveness research seeks to provide head-to-head comparisons of treatment outcomes in routine care. Health-care utilization databases record drug use and selected health outcomes for large populations in a timely way and reflect routine care, and therefore may be the preferred data source for comparative effectiveness research. Confounding caused by selective prescribing based on indication, severity, and prognosis threatens the validity of non-randomized database studies that often have limited details on clinical information. Several recent developments may bring the field closer to acceptable validity, including approaches that exploit the concepts of proxy variables using high-dimensional propensity scores, within-patient variation of drug exposure using crossover designs, and between-provider variation in prescribing preference using instrumental variable (IV) analyses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simulation study of the number of events per variable in logistic regression analysis
Peduzzi, P., Concato, J., Kemper, E., Holford, T. R., & Feinstein, A. R. (1996) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00236-3 · Cited by 9,655
Estimating causal effects of treatments in randomized and nonrandomized studies
Rubin, D. B. (1974) · Journal of Educational Psychology · doi:10.1037/h0037350 · Cited by 9,436
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Identification of Causal Effects Using Instrumental Variables
Angrist, J. D., Imbens, G. W., & Rubin, D. B. (1996) · Journal of the American Statistical Association · doi:10.1080/01621459.1996.10476902 · Cited by 4,230
Causal Diagrams for Epidemiologic Research
Greenland, S., Pearl, J., & Robins, J. M. (1999) · Epidemiology · doi:10.1097/00001648-199901000-00008 · Cited by 3,728
Angrist, J. D., & Krueger, A. B. (2001) · Journal of Economic Perspectives · doi:10.1257/jep.15.4.69 · Cited by 2,355
The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events
Maclure, M. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115853 · Cited by 2,327
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Network meta‐analysis for indirect treatment comparisons
Lumley, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1201 · Cited by 1,206
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Subgroup analysis in randomised controlled trials: importance, indications, and interpretation
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17709-5 · Cited by 942
Cepeda, M. S. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg115 · Cited by 859 · cited 1×
“proxies, can be modeled simultaneously without the risk of overfitting, if there were fewer than 10 outcomes per variable in a traditional outcome model.(54,59)”
BackgroundWhen are observational studies as credible as randomised trials?
Vandenbroucke, J. P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16261-2 · Cited by 538 · cited 2×
“Conversely, because prescribing of COX-2 inhibitors was initially not influenced by considerations of the patients’ risk for myocardial infarction (MI), such unintended effects are much less likely to be confounded.(27) The issue of confounding by indication is further complicated when studying newly approved drugs th…”
BackgroundAssessment and Control for Confounding by Indication in Observational Studies
Psaty, B. M., Koepsell, T. D., Lin, D., Weiss, N. S., Siscovick, D. S., Rosendaal, F. R., Pahor, M., & Furberg, C. D. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb01603.x · Cited by 363
Cited by
Angrist, J. D., & Krueger, A. B. (2001) · Journal of Economic Perspectives · doi:10.1257/jep.15.4.69 · Cited by 2,355
Avoiding Invalid Instruments and Coping with Weak Instruments
Murray, M. P. (2006) · Journal of Economic Perspectives · doi:10.1257/jep.20.4.111 · Cited by 1,092
Assessing the Gold Standard — Lessons from the History of RCTs
Bothwell, L. E., Greene, J. A., Podolsky, S. H., & Jones, D. S. (2016) · New England Journal of Medicine · doi:10.1056/nejmms1604593 · Cited by 664
Berger, M. L., Mamdani, M., Atkins, D., & Johnson, M. L. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00600.x · Cited by 409
Solomon, D. H. (2011) · JAMA · doi:10.1001/jama.2011.878 · Cited by 393
Metadata
- Authors
- Schneeweiss, S.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-06-06
- Volume
- 82
- Issue
- 2
- Pages
- 143-156
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2016418114
- Cited by
- 197
- References
- 14
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.